Epigenetic Regulation in Hematologic Malignancies

Dear Colleagues,

We are pleased to announce the call for submissions to a Special Issue of Cancers focused on the topic of "Epigenetic Regulation in Hematologic Malignancies." Epigenetic mechanisms play a critical role in the development, progression, and treatment response of hematologic malignancies. DNA methylation, histone modifications, and non-coding RNA regulation have emerged as key regulators in this context. Understanding the epigenetic regulation in hematologic malignancies holds significant potential for the development of novel therapeutic approaches and improved patient outcomes.

This Special Issue aims to provide a comprehensive overview of current research and advancements in the field of epigenetic regulation in hematologic malignancies. We invite the submission of original research articles and reviews covering various aspects of this topic, including but not limited to:

• 1. Epigenetic alterations in hematologic malignancies;
• 2. Interplay between malignant cells and the tumor microenvironment mediated by epigenetic modifications;
• 3. The role of non-coding RNAs in modulating the tumor microenvironment in hematologic malignancies;
• 4. Epigenetic regulation of immune responses in hematologic malignancies;
• 5. Therapeutic targeting of epigenetic regulators in hematologic malignancies.

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians, and experts in the field of hematologic malignancies and epigenetics.

By consolidating the latest research findings and clinical experiences, we aim to deepen our understanding of the intricate interplay between epigenetic alterations and hematologic malignancies. Furthermore, we anticipate that this Special Issue will facilitate the development of innovative therapeutic strategies targeting the epigenetic regulation in hematologic malignancies.

If you have any questions, require further information, or need any assistance, please do not hesitate to reach out to us. Our team is dedicated to supporting and facilitating your participation in this Special Issue.

Thank you for your attention to this matter, and we eagerly await your valuable submissions.

Dr. Travis S. Johnso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• epigenetic regulation
• hematologic malignancies
• DNA methylation
• non-coding RNA
• therapeutic targeting